Details of the Drug

General Information of Drug (ID: DMB7WYM)

Drug Name
ATOSIBAN
Synonyms
Atosiban; Tractocile; 90779-69-4; Atosiban acetate; Antocin; UNII-081D12SI0Z; Rwj 22164; Orf-22164; RWJ-22164; CHEMBL382301; 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin; dTVT; 081D12SI0Z; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; NCGC00165718-01; Atosibanum [INN-Latin]; ORF 22164; deTVT; Atosibanum; Antocin II; Atosiban [USAN:INN:BAN]; RWJ22164; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineox
ATC Code
G02CX01: ATOSIBAN
G02CX: Other gynecologicals
G02C: OTHER GYNECOLOGICALS
G02: OTHER GYNECOLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 994.2
Logarithm of the Partition Coefficient (xlogp) -1.9
Rotatable Bond Count (rotbonds) 18
Hydrogen Bond Donor Count (hbonddonor) 11
Hydrogen Bond Acceptor Count (hbondacc) 15
ADMET Property
Clearance
The clearance of drug is 41.8 L/h [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.21 hours (alpha), and 1.7 hours (beta) [1]
Metabolism
The drug is metabolized via prior cleavage of the disulfide bridge [1]
Vd
The volume of distribution (Vd) of drug is 41.8 L [1]
Chemical Identifiers
Formula
C43H67N11O12S2
IUPAC Name
(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
Canonical SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
InChI
InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
InChIKey
VWXRQYYUEIYXCZ-OBIMUBPZSA-N
Cross-matching ID
PubChem CID
5311010
ChEBI ID
CHEBI:135899
CAS Number
90779-69-4
UNII
081D12SI0Z
DrugBank ID
DB09059
TTD ID
D0D8XY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Inhibitor [2]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Inhibitor [3]
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Inhibitor [3]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vasopressin V1b receptor (V1BR) DTT AVPR1B 5.14E-01 -0.03 -0.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 EMA: Tractocile Product Information
2 Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
3 The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.